Reported outcomes of studies for infant ALL
| Study (year of study) . | Patients (N) . | KMT2Ar/tested (%) . | Complete remission, % . | Induction death, % . | Death in remission, % . | EFS, % (SE) (all patients) . | EFS, % (SE) (KMT2Ar) . | OS, % (SE) (all patients) . | HCT performed, % . |
|---|---|---|---|---|---|---|---|---|---|
| BFM 83, 86, and 90 (1983 to 1995)3 | 106 | 29/59 (49.2) | 95.2 | NA | 3.8 | 43 (5) (6-y) | PGR: 41 (12) | 48 (6) (6-y) | NA |
| PPR: 9 (9) | |||||||||
| (6-y) | |||||||||
| CCG 1953 (1996 to 2000)4 | 115 | 79/115 (68.7) | 82.5 | 8.7 | 34.8* | 41.7 (9.2) (5-y) | 33.6 (NA) (5-y) | 44.8 (5.6) (5-y) | 33.0 |
| Interfant-99 (1999 to 2005)5 | 482 | 314/396 (79.3) | 93.9 | 3.8 | 5.2 | 47.0 (2.6) (4-y) | 36.9 (3.1) (4-y) | 55.3 (2.7) (4-y) | 8.5 |
| Interfant-06 (2006 to 2016)6 | 651 | 476/643 (74.0) | 92.9 | 3.7 | 7.1 | 46.1 (2.1) (6-y) | 36.4 (2.3) (6-y) | 58.2 (2.0) (6-y) | 17.1 |
| MLL-10 (2011 to 2015)1 | 90 | 75/90 (83.3) | 91.1 | 0.0 | 2.2 | 70.9 (4.9) (5-y) | 66.2 (5.6) (5-y) | 85.0 (3.9) (5-y) | 47.8 |
| Study (year of study) . | Patients (N) . | KMT2Ar/tested (%) . | Complete remission, % . | Induction death, % . | Death in remission, % . | EFS, % (SE) (all patients) . | EFS, % (SE) (KMT2Ar) . | OS, % (SE) (all patients) . | HCT performed, % . |
|---|---|---|---|---|---|---|---|---|---|
| BFM 83, 86, and 90 (1983 to 1995)3 | 106 | 29/59 (49.2) | 95.2 | NA | 3.8 | 43 (5) (6-y) | PGR: 41 (12) | 48 (6) (6-y) | NA |
| PPR: 9 (9) | |||||||||
| (6-y) | |||||||||
| CCG 1953 (1996 to 2000)4 | 115 | 79/115 (68.7) | 82.5 | 8.7 | 34.8* | 41.7 (9.2) (5-y) | 33.6 (NA) (5-y) | 44.8 (5.6) (5-y) | 33.0 |
| Interfant-99 (1999 to 2005)5 | 482 | 314/396 (79.3) | 93.9 | 3.8 | 5.2 | 47.0 (2.6) (4-y) | 36.9 (3.1) (4-y) | 55.3 (2.7) (4-y) | 8.5 |
| Interfant-06 (2006 to 2016)6 | 651 | 476/643 (74.0) | 92.9 | 3.7 | 7.1 | 46.1 (2.1) (6-y) | 36.4 (2.3) (6-y) | 58.2 (2.0) (6-y) | 17.1 |
| MLL-10 (2011 to 2015)1 | 90 | 75/90 (83.3) | 91.1 | 0.0 | 2.2 | 70.9 (4.9) (5-y) | 66.2 (5.6) (5-y) | 85.0 (3.9) (5-y) | 47.8 |
BFM, Berlin-Frankfurt-Münster; CCG, Children's Cancer Group; EFS, event-free survival; KMT2Ar, KMT2A rearrangement; N, number; NA, not available; OS, overall survival; PGR, prednisone good response; PPR, prednisone poor response; SE, standard error.
Any toxic death including induction therapy.